Granted Patent
B2
US 12,497,399 · App. 18/212,324 · Granted Dec 16, 2025
Fluorinated integrin antagonists
Inventors:
Ben C. Askew (Marshfield, MA); Richard W. Heidebrecht (Somerville, MA); Takeru Furuya (Cambridge, MA); Mark E. Duggan (Tequesta, FL); D. Scott Edwards (Bedford, MA)
Assignee:
OcuTerra Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Claims (17)
1 . A compound of formula I:
or a pharmaceutically acceptable salt or solvate thereof, wherein:
Z is
R and R′ are each independently H or F;
Q is
and
X is N;
Y is CH;
R 1 is C 1 -C 6 alkoxy substituted with 1, 2, or 3 fluorine atoms;
R 2 and R 3 are each independently H, F, CH 2 F, CHF 2 , or CF 3 , provided that one of R 2 and
R 3 is not H,
provided that the compound of formula (I) contains at least one fluorine atom.
2 . A compound represented by:
or a pharmaceutically acceptable salt thereof.
3 . A compound represented by:
4 . A pharmaceutical composition comprising a compound according to claim 2 and one or more pharmaceutically acceptable carrier or excipient.
5 . A pharmaceutical composition comprising a compound according to claim 3 and one or more pharmaceutically acceptable carrier or excipient.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 12, 2026
From: OCUTERRA THERAPEUTICS, INC. (FORMERLY KNOWN AS SCIFLUOR LIFE SCIENCES, INC.)
To: FELIQS CORPORATION
Reel/Frame 073443/0692 →
CHANGE OF NAME
Recorded Aug 2, 2023
From: SCIFLUOR LIFE SCIENCES, INC.
To: OCUTERRA THERAPEUTICS, INC.
Reel/Frame 064467/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 2, 2023
From: ASKEW, BEN C.; HEIDEBRECHT, RICHARD; FURUYA, TAKERU; DUGGAN, MARK E.; EDWARDS, D. SCOTT
To: SCIFLUOR LIFE SCIENCES, INC.
Reel/Frame 064469/0047 →
Continuity (10)
Continuation
16717403
· Dec 17, 2019
Continuation
16133094
· Sep 17, 2018
Continuation
14766322
Provisional Application
61762087
· Feb 7, 2013
Provisional Application
61900706
· Nov 6, 2013
References Cited (178)
US 4937266A
· Tomikawa et al.
· 1990
[cited by applicant]
US 5374660A
· Murad et al.
· 1994
[cited by applicant]
US 5501969A
· Hastings et al.
· 1996
[cited by applicant]
US 5571846A
· Murad et al.
· 1996
[cited by applicant]
US 5645839A
· Chobanian et al.
· 1997
[cited by applicant]
US 5736357A
· Broemme et al.
· 1998
[cited by applicant]
US 6017926A
· Askew et al.
· 2000
[cited by applicant]
US 6066648A
· Duggan et al.
· 2000
[cited by applicant]
US 6117445A
· Neely
· 2000
[cited by applicant]
US 6139847A
· Chobanian et al.
· 2000
[cited by applicant]
US 6211184B1
· Duggan et al.
· 2001
[cited by applicant]
US 6268342B1
· Culler et al.
· 2001
[cited by applicant]
US 6268378B1
· Duggan et al.
· 2001
[cited by applicant]
US 6291503B1
· Schoop et al.
· 2001
[cited by applicant]
US 6297249B1
· Duggan et al.
· 2001
[cited by applicant]
US 6303126B1
· Nakamura et al.
· 2001
[cited by applicant]
US 6407241B1
· Jensen et al.
· 2002
[cited by applicant]
US 6410526B1
· Duggan et al.
· 2002
[cited by applicant]
US 6426353B1
· Arison et al.
· 2002
[cited by applicant]
US 6472403B2
· Duggan et al.
· 2002
[cited by applicant]
US 6500835B2
· Fukami et al.
· 2002
[cited by applicant]
US 6664227B1
· Wynn et al.
· 2003
[cited by applicant]
US 7056909B2
· Wang
· 2006
[cited by applicant]
US 8901144B2
· Askew et al.
· 2014
[cited by applicant]
US 9266884B2
· Askew et al.
· 2016
[cited by applicant]
US 9518053B2
· Askew
· 2016
[cited by examiner]
US 9572801B2
· Askew et al.
· 2017
[cited by applicant]
US 9593114B2
· Askew et al.
· 2017
[cited by applicant]
US 9717729B2
· Askew
· 2017
[cited by examiner]
US 9790222B2
· Askew et al.
· 2017
[cited by applicant]
US 9802933B2
· Askew et al.
· 2017
[cited by applicant]
US 20010053853A1
· Askew et al.
· 2001
[cited by applicant]
US 20020016461A1
· Albers et al.
· 2002
[cited by applicant]
US 20020037889A1
· Duggan et al.
· 2002
[cited by applicant]
US 20020040030A1
· Coleman et al.
· 2002
[cited by applicant]
US 20020040039A1
· Hartman et al.
· 2002
[cited by applicant]
US 20020049224A1
· Arison et al.
· 2002
[cited by applicant]
US 20040053968A1
· Hartman et al.
· 2004
[cited by applicant]
US 20050004199A1
· Hartman et al.
· 2005
[cited by applicant]
US 20050043344A1
· Boys et al.
· 2005
[cited by applicant]
US 20060030581A1
· DeBusi et al.
· 2006
[cited by applicant]
US 20070117849A1
· Goodman et al.
· 2007
[cited by applicant]
US 20190225609A1
· Askew et al.
· 2019
[cited by applicant]
US 20190263810A1
· Askew et al.
· 2019
[cited by applicant]
US 20210246132A1
· Askew et al.
· 2021
[cited by applicant]
CN 1284955A
· 2001
[cited by applicant]
CN 1589145A
· 2005
[cited by applicant]
EP 1040098A1
· 2000
[cited by applicant]
WO WO9613523A1
· 1996
[cited by applicant]
WO WO9930709A1
· 1999
[cited by applicant]
WO WO9931061A1
· 1999
[cited by applicant]
WO WO9931099A1
· 1999
[cited by applicant]
WO WO0147867A1
· 2001
[cited by applicant]
WO WO0187840A1
· 2001
[cited by applicant]
WO WO0207730A1
· 2002
[cited by applicant]
WO WO2004058254A1
· 2004
[cited by applicant]
WO WO2011060395A1
· 2011
[cited by applicant]
WO WO2011150156A2
· 2011
[cited by applicant]
WO WO2013000909A1
· 2013
[cited by applicant]
WO WO2014124302A1
· 2014
[cited by applicant]
Abdollahi et al., “Inhibition of avβ3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy”, Clinical Cancer Research, 2005, 11:6270-6279.
[cited by applicant]
Adams J. et al., “Structure Activity Relationships of av Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents”, ACS Medicinal Chemistry Letters, 2014, 5(11):1207-1212.
[cited by applicant]
Ali, Y. et al. “Industrial Perspective in Ocular Drug Delivery,” Advanced Drug Delivery Reviews, 2006, 58:1258-1268.
[cited by applicant]
Ando, M. et al., “Facile one-pot synthesis of N-difluoromethyl-2-pyridone derivatives” Organic Letters, 2006, 8(17):3805-3808.
[cited by applicant]
Bourges, J.L. et al., “Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles,” Invest. Ophthalmol. Vis. Sci., 2003, 44:3562-3569.
[cited by applicant]
Bradshaw, B. et al., “Synthesis of 5-hydroxy-2,3,4,5-tetrahydro-[1H]-2-benzazepin-4-ones: selective antagonists of muscarinic (M3) receptors,” Ora. Biomol. Chem., 2008, 6(12):2138-2157.
[cited by applicant]
Brinkmann et al., “Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis”, Nature Reviews, Drug Discovery, 2010, 9:883-897.
[cited by applicant]
Bunz, “The Cancer Gene Theory”, Principles of Cancer Genetics, 2008, 1 :1-47.
[cited by applicant]
Campochiaro, P.A., et al., “Reduction of Diabetic Macular Edema by Oral Administration of the Kinase Inhibitor PKC412,” Invest. Ophthalmol., Vis. Sci., 2004, 45:922-931.
[cited by applicant]
Cao, F., et al. “Zn—Al—NO
[cited by applicant]
Chavakis, E. et al., “Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides,” Diabetologia, 2002, 45:262-267.
[cited by applicant]
Chen, H. et al., “ FIC1 and BSEP defects in Taiwanese patients with chronic intrahepatic cholestasis with low gamma-glutamyltranspeptidase levels”, J. Ped., 2002, 140:119-124.
[cited by applicant]
Chu et al., “Interaction of West Nile Virus with αvβ3 Integrin Mediates Virus Entry into Cells”, The Journal of Biological Chemistry, 2004, 279(52):54533-54541.
[cited by applicant]
Coleman, P.J. et al. “Nonpeptide avβ3 Antagonists. Part 11: Discovery and Preclinical Evaluation of potent avβ3 Antagonists for the Prevention and Treatment of Osteoporosis,” J. Med. Chem., 2004, 47:4829-4837.
[cited by applicant]
Coughlin et al., “Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy”, Breast Cancer Research Treatment, 2010,…
[cited by applicant]
D'Ambrosio et al., “Chemokine receptors in inflammation: an overview”, Journal of Immunological Methods, 2003, 273:3-13.
[cited by applicant]
Data from the National Cancer Institute (http://www.cancer.gov/) (Downloaded May 29, 2014).
[cited by applicant]
Diebold, Y. et al., “Applications of nanoparticles in ophthalmology,” Progress in Retinal and Eye Research, 2010, 29:596-609.
[cited by applicant]
Dorrell, M., “Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, 2007, 104(3):967-972.
[cited by applicant]
Doukas, J., et al., “Topical Administration of a Multi-Targeted Kinase Inhibitor Suppresses Choroidal Neovascularization and Retinal Edema,” Journal of Cellular Physiology, 2008, 216:29-37.
[cited by applicant]
Duan et al., “Association of avβ3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells”, Clinical & Experimental Metastasis, 2004, 21 :747-753.
[cited by applicant]
Felding-Habermann, “Involvement of tumor cell integrin avβ3 in hematogenous metastasis of human melanoma cells”, Clinical & Experimental Metastasis, 2002, 19:427-436.
[cited by applicant]
Freund, K.B. et al., “Age-related Macular Degeneration and Choroidal Neovascularization,” American Journal of Ophthalmology, 1993, 115:786-791.
[cited by applicant]
Friedlander, M. et al. “Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases”. Proc Natl Acad Sci USA, 1996, 93:9764-9769.
[cited by applicant]
Friedlander, P., “Ueber o-Amidobenzaldehyd”, Ber. Dtsch. Chem. Ges. 1882, 15:2572.
[cited by applicant]
Fu, Y., et al., “Angiogenesis Inhibition and Choroidal Neovascularization Suppression by Sustained Delivery of an Integrin Antagonist, EMD478761,” Invest. Ophthalmol. Vis. Sci., 2007, 48(11):5184-5190.
[cited by applicant]
Gaudana, R. et al., “Recent perspectives in ocular drug delivery,” Pharm Res., 2009, 26(5):1197-1216.
[cited by applicant]
Hahm, K. et al., αvβ6 Integrin Regulates Renal Fibrosis and Inflammation in Alport Mouse, Am. J. Pathol. 2007, 170(1):110-125.
[cited by applicant]
Hallinan, E.A. et al., “N-Substituted dibenzoxazepine as analgesic PGE2 antagonists,” J. Med. Chem., 1993, 36:3293-3299.
[cited by applicant]
Hariharan et al., “Assessment of the biological and pharmacological effects of the αvβ5 and αvβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors”, Annals of Oncology, 2006,…
[cited by applicant]
Haynes et al., Bone Resorption in, Wiley Encyclopedia of Biomedical Engineering (M. Akay ed., 2006).
[cited by applicant]
Henderson, N. et al., “Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs”, Nat. Med. 2013, 19(12):1617-1627.
[cited by applicant]
Hodivala-Dilke, “αvβ3 integrin and angiogenesis: a moody integrin in a changing environment”, Current Opinion in Cell Biology, 2008, 20:514-519.
[cited by applicant]
Hutchison, John H., et al., Nonpeptide avβ3 Antagonists. 8. In Vitro and In Vivo Evaluation of a Potent αvβ3 Antagonist for the Prevention and Treatment of Osteoporosis, J. Med. Chem., 2003, 46:4790-4798.
[cited by applicant]
Hynes, “Integrins: Bidirectional, Allosteric Signaling Machines”, Cell, 2002, 110:673-687.
[cited by applicant]
Jacot, J.L. et al., “Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy,” Journal of Ophthalmology, vol. 2011, Article ID 589813, 2011.
[cited by applicant]
Jubb et al., “Predicting benefit from antiangiogenic agents in malignancy”, Nature Reviews/Cancer, 2006, 6:626-635.
[cited by applicant]
Judge et al., “Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment”, Pharmacology & Therapeutics, 2006, 111:224-259.
[cited by applicant]
Kamizuru, H.K.H. et al., “Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the Rat.,” Investigative Ophthalmology & Visual Science, 2001, 42:2664-2672.
[cited by applicant]
Kaur, H., et al., “Niosomes: A Novel Drug Delivery System,” Int J Pharm Sci Rev Res., 2012, 15(1):113-120.
[cited by applicant]
Kern, T.S., et al., “Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology,” Diabetes, 2007, 56(2):373-379.
[cited by applicant]
Klein, R. et al., “The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy,” Arch Ophthalmol, 1994, 12:1217-1228.
[cited by applicant]
Koelink et al., “Targeting chemokine receptors in chronic inflammatory diseases: An extensive review”, Pharmacology & Therapeutics, 2012, 133:1-18.
[cited by applicant]
Kumar, C. et al., “Biochemical Characterization of the Binding of Echistatin to Integrin αvβ3 Receptor”, J. Pharmacol. Exp. Ther. 1997, 283(2):843-853.
[cited by applicant]
Kuppen et al., “Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer”, Histochemistry and Cell Biology, 2001, 115:67-72.
[cited by applicant]
Linderman, R.J., “Oxidation of Fluoroalkyl-Substituted Carbinols by the Dess-Martin Reagent,” J. Org. Chem., 1989, 54(3):661-668.
[cited by applicant]
Lissoni et al, “Biotherapy with the pineal hormone melatonin plus aloe and myrrh tincture in untreatable metastatic cancer patients as an essence therapy of cancer”, Cancer Research, 2009, 7:397-401.
[cited by applicant]
Lorger et al., Activation of tumor cell integrin avβ3 controls angiogenesis and metastatic growth in the brain, PNAS, 2009, 106:10666-10671.
[cited by applicant]
Luna, J. et al. “Antagonists of Integrin αvβ3 Inhibit Retinal Neovascularization in a Murine Model,” Laboratory investigation, 1996, 75(4):563-573.
[cited by applicant]
Luo et al., “Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction”, Cell, 2009, 136:823-837.
[cited by applicant]
Lyons et al., “Integrins in metastatic adenoid cystic carcinoma”, International Journal of Oral and Maxillofacial Surgery, 2005, 34:912-914.
[cited by applicant]
Marelli et al., “Tumor targeting via integrin ligands”, Frontiers in Oncology, 2013, 3:1-12.
[cited by applicant]
Max et al., “Immunohistochemical analysis of integrin αvβ3 expression on tumor-associated vessels of human carcinomas”, International Journal of Cancer, 1997, 71:320-324.
[cited by applicant]
McDermott et al., “Personalized Cancer Therapy with Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology”, Journal of Clinical Oncology, 2009, 27:5650-5659.
[cited by applicant]
Meissner, R.S. et al., “Nonpeptide αvβ3 Antagonists. Part 2: Constrained Glycyl Amides Derived from the RGD Tripeptide”, Bioorganic & Medicinal Chemistry Letters, 2002, 12:25-29.
[cited by applicant]
Millauer, B., et al., “Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types in Vivo”, Cancer Research, 1996, 56:1615-1620.
[cited by applicant]
Moors et al., “Structure-Based Site of Metabolism Prediction for Cytochrome P450 2D6”, Journal of Medicinal Chemistry, 2011, 54(17):6098-6105.
[cited by applicant]
Mousa, “Cell Adhesion Molecules: Potential Therapeutic & Diagnostic Implications”, Molecular Biotechnology, 2008, 38:33-40.
[cited by applicant]
Muller et al., Antiviral Strategies in, Antiviral Strategies 1-24, 4 (H.-G. Krausslich et al., eds., 2009).
[cited by applicant]
Murphy, M.G., et al., “Effect of L-000845704, an αvβ3 Integrin Antagonist, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women,” The Journal of Clinical Endocrinology & Metabolism, …
[cited by applicant]
Nahm, S., et al., “N-methoxy-N-methyl amides as effective acylating agents,” Tetrahedron Letters, 1981, 22(39):3815-3818.
[cited by applicant]
Noutsias M. et al. “Human Coxsackie-Adenovirus Receptor is Colocalized with αvβ3 and αvβ5 on the Cardiomyocyte Sarcolemma and Upregulated in Dilated Cardiomyopathy Implications for Cardiotropic Viral Infections”, Circul…
[cited by applicant]
Parry C. et al. “Herpes simplex virus type 1 glycoprotein H binds to αvβ3 integrins”, Journal of General Virology, 2005, 86:7-10.
[cited by applicant]
Pialat, A. et al., “Oxidative para-Triflation of Acetanilides,” Organic Letters, 2013, 15:1764-1767.
[cited by applicant]
Poynard, T. et al., “Natural history of liver fibrosis progression in patients with chronic hepatitis C”, The Lancet 1997, 349:825-832.
[cited by applicant]
Prasasya et al., “Analysis of cancer signaling networks by systems biology to develop therapies”, Seminars in Cancer Biology, 2011, 21: 200-206.
[cited by applicant]
Rabinow, Barrett E., “Nanosuspensions in Drug delivery,” Nature Reviews Drug Discovery, 2004, 3:785-796.
[cited by applicant]
Registry No. 227963-76-0 (Entered STN Jul. 16, 1999).
[cited by applicant]
Reinmuth et al., “αvβ3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice”, Cancer Research, 2003, 63:2079-2087.
[cited by applicant]
Riecke, B. et al. “Topical Application of Integrin Antagonists Inhibit Proliferative Retinopathy,” Harm Metab Res., 2001, 33:307-311.
[cited by applicant]
Rognoni, E. et al., “Kindlin-1 controls Wnt and TGF-β availability to regulate cutaneous stem cell proliferation”, Nat. Med. 2014, 20(4):350-359.
[cited by applicant]
Rolli et al., “Activated integrin αvβ3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells”, PNAS, 2003, 100:9482-9487.
[cited by applicant]
Rowe, Raymond C., “Handbook of Pharmaceutical Excipients”, Fifth Edition, Pharmaceutical Press and American Pharmacists Association (2006).
[cited by applicant]
Santulli et al., “Evaluation of the anti-angiogenic properties of the new selective αvβ3 integrin antagonist RGDechiHCit”, Journal of Translational Medicine, 2011, 9:1-10.
[cited by applicant]
Santulli, R. et al., “Studies with an Orally Bioavailable αv Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats,” The Journ…
[cited by applicant]
Sato, I. et al., “Enantioselective Synthesis of Substituted 3-Quinolyl Alkanols and Their Application to Asymmetric Autocatalysis,” Synthesis, 2004, 9:1419-1428.
[cited by applicant]
Sawyers, “The Cancer Biomarker Problem”, Nature, 2008, 548-552.
[cited by applicant]
Seebach, D. et al., “Total Synthesis of Myxovirescins, 1 Strategy and Construction of the “Southeastern” Part [O(1)-C(14)]”, Liebigs Annalen der Chemie, 1994, 701-717.
[cited by applicant]
Sondej, S.C. et al., “Gem-Difluoro Compounds: A Convenient Preparation from Ketones and Aldehydes by Halogen Fluoride Treatment of 1,3-dithiolanes,” J. Org. Chem., 1986, 51:3508-3513.
[cited by applicant]
Soussi, “p53 Antibodies in the Sera of Patients with Various Types of Cancer: A Review”, Cancer Research, 2000, 60:1777-1788.
[cited by applicant]
Speicher, M.A. et al. “Pharmacologic therapy for diabetic retinopathy,” Expert Opin. Emerging Drugs, 2003, 8(1):239-250.
[cited by applicant]
Stragies, R. et al. “Design and Synthesis of a New Class of Selective Integrin α5β1 antagonists”, J. Med. Chem., 2007, 50:3786-3794.
[cited by applicant]
Stupp et al., “Integrin Inhibitors Reaching the Clinic”, Journal of Clinical Oncology, 2007, 25:1637-1638.
[cited by applicant]
Summerford C. et al. “αvβ5 integrin: a co-receptor for adeno-associated virus type 2 infection”, Nature Medicine, 1999, 5(1):78-82.
[cited by applicant]
Surendran, K. et al., “A role for Wnt-4 in renal fibrosis”, Am. J. Physiol. Renal Physiol. 2002, 46, 270-278.
[cited by applicant]
Sutherland et al., “Management of Chronic Obstructive Pulmonary Disease”, The New England Journal of Medicine, 2004, 350:2689-2697.
[cited by applicant]
Takagi, H. et al., “Role of vitronectin receptor-type integrins and osteopontin in ischemia-induced retinal neovascularization,” Japanese Ophthalmological Society, 2002, 46:270-278.
[cited by applicant]
Takahashi, Ket al. “Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib,” Arch. Ophthalmol., 2009, 127(4):494-499.
[cited by applicant]
Takayama et al., “The Relationship Between Bone Metastasis from Human Breast Cancer and Integrin αvβ3 Expression”, Anticancer Research, 2005, 25:79-84.
[cited by applicant]
Vandamme, Th. F., “Microemulsions as ocular drug delivery systems: recent developments and future challenges,” Progress in Retinal and Eye Research, 2002, 21:15-34.
[cited by applicant]
Wagh, V.D. et al. “Niosomes as ophthalmic drug delivery systems: a review,” Journal of Pharmacy Research, 2010, 3(7):1558-1563.
[cited by applicant]
Wang et al., “Mathematical modeling in cancer drug discovery”, Drug Discovery Today, 2014, 19:145-150.
[cited by applicant]
Wang, W. et al. “The Antiangiogenic Effects of Integrin a5β1 Inhibitor (ATN-161) In Vitro and In Vivo,” Invest. Ophthalmol. Vis. Sci., 2011, 52(10):7213-7220, Published online before print Aug. 3, 2011.
[cited by applicant]
Ward et al., “Inflammation and αvβ3 Integrin”, American Journal of Respiratory and Critical Care Medicine, 2012, 185:5-6.
[cited by applicant]
Wayner, E. et al., “integrins αvβ5 and αvβ6 Contribute to Cell Attachment to Vitronectin but Differentially Distribute on the Cell Surface”, J. Cell. Biol. 1991, 113(4):919-929.
[cited by applicant]
Wilder R. et al. “Integrin αvβ3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases”, Ann Rheum Dis., 2002, 61(Suppl. II):96-99.
[cited by applicant]
Williams, R. et al. “Epidemiology of diabetic retinopathy and macular oedema: a review,” Eye, 2004, 18:963-983.
[cited by applicant]
Yang, X.M., “Role of PI3K/Akt and MEK/ERK in Mediating Hypoxia-Induced Expression of HIF-1α and VEGF in Laser-Induced Rat Choroidal Neovascularization,” Investigative Ophthalmology & Visual Science, 2009, 50(4):1873-187…
[cited by applicant]
Yanni, S.E. et al., “The effects of nepafenac and amfenac on retinal angiogenesis,” Elsevier, Brain Research Bulletin, 2010, 81:310-319.
[cited by applicant]
Yasuda, N., et al., “An Efficient Synthesis of an avβ3 Antagonist,” J. Org. Chem., 2004, 69:1959-1966.
[cited by applicant]
Yasukawa, T, et al. “Inhibition of experimental choroidal neovascularization in rats by an alpha(v)-integrin antagonist,” Current Eye Research, 2004, 28(5):359-366.
[cited by applicant]
Zarbin, M.A. “Current Concepts in the Pathogenesis of Age-Related Macular Degeneration”, Arch. Ophthalmol., 2004, 122:598-614.
[cited by applicant]
Zhao et al., “Exploring the Formation of Multiple Layer Hydrates for a Complex Pharmaceutical Compound”, The Journal of Physical Chemistry B, 2009, 113(17):5929-5937.
[cited by applicant]
Zhou, Hong-Yan et al., “Nanoparticles in the ocular drug delivery,” Int. J. Ophthalmol., 2013, 6(3):390-396.
[cited by applicant]